CVS Health announced Wednesday that it is breaking itself into two companies, reversing a roughly two-decade shopping spree that included a $69 billion purchase of Aetna. The company swears nothing will change for the people who actually buy their pills there. So the question becomes why anyone just spent a billion hours of executive time on a divorce that, by the company's own account, changes nothing for customers.
Two Companies, One Very Expensive U-Turn
Here's the setup, according to CNN. One company, called CVS Pharmacy, will hold the 9,000 retail stores, the mail order pharmacy, the specialty drug business and MinuteClinic. The other will hold Aetna, Caremark, and two acquired companies that provide primary care and in-home health evaluations for seniors. That second one will be called CVS Health for now, a name that sounds like a placeholder because it basically is.
The separation is expected to close in early 2028. That's more than a year of lawyers, bankers and consultants billing by the hour to turn one company into two. Somewhere a consulting firm is already ordering a bigger yacht.
CEO David Joyner described the whole thing in the most corporate sentence ever uttered: "We're basically taking what I believe is one great company and making it two." Sir, that is also what a cell does when it's dying of something. Or reproducing. We genuinely can't tell which one he's going for.
The Merger Machine That Ate American Healthcare
Quick history lesson. In 2007, CVS merged with Caremark, a pharmacy benefit manager. In 2018, it bought Aetna for $69 billion. The pitch was a seamless healthcare empire: the insurer, the middleman and the drugstore all under one roof, saving you money and making your life easier.
That is not what happened. Consolidation like this has come under heavy fire from consumer advocates and state and federal lawmakers, who argue these conglomerates wield far too much control over the sector and drive up costs for patients. Some members of Congress have openly called for breaking the companies up.
So the company that spent years assembling the thing is now taking it apart while insisting the thing was great. Both of those can't be true. Pick one.
Nothing Changes, Says the Company Doing the Changing
Let's be clear about what this means for you, the person standing at the counter wondering why a bottle of antibiotics costs more than a nice dinner. Nothing. The company didn't announce any store closures, and the split won't affect what patients pay for prescriptions.
That's because the pharmacy benefit manager side works on the backend, negotiating directly with drugmakers over prices, while the drugstores and Caremark already operate separately. Splitting the corporate parent into two doesn't touch how any of it functions.
So if the split doesn't lower your costs, doesn't change how you shop, and doesn't alter how the business runs day to day, what exactly is it for? Hold that thought. We'll get there.
Wall Street's Reaction: A 12 Percent Faceplant
Shares of CVS fell 12% in midday trading after initially ticking up before the opening bell. That's the market looking at the announcement and collectively saying "wait, what?"
Leerink Partners analyst Michael Cherny called the news "a complete shock" in a note to clients. He did add that CVS's pharmacy business has been performing well, so the outlook for a standalone retail pharmacy might actually be stronger than before. Fair enough. A shock can still be a decent idea.
The timing is the weird part. CVS reported higher third-quarter earnings and revenue the same day, mostly thanks to its Health Care Benefits segment, and raised its earnings guidance for the rest of the year. The company is doing fine, and its response was to blow itself up. Shareholders will get shares of both companies in a tax-free transaction, which should soften the blow for them. Everyone else gets a new logo.
The Pressure Cooker Behind the Breakup
There is a reason the timing makes sense, and it isn't love of the customer. Health insurers are under cost pressure because Americans are using more healthcare services. Lawmakers and regulators are pushing to reform the pharmacy benefit manager industry, just as new competitors try to chip away at the dominance of Caremark and the other big PBMs.
Meanwhile the retail side is getting pummeled by online shopping, where CVS still lags leaders like Amazon. Joyner took over in 2024 after layoffs, store closings and lousy stock performance, so this is the guy's big swing.
Put those pressures together and the picture sharpens. The regulatory heat is aimed squarely at the combined structure. A company that sits on both sides of the prescription transaction makes a very large and very obvious target.
The Dingo Take
Who benefits from this? Not you, because the company itself says your prescription prices won't move. Not the 200,000 people working in CVS stores, who just got news that their employer is being split in half by executives promising nothing will change. The people who benefit are the ones holding shares of both companies and the ones who'd rather not have Congress staring at a single giant that owns the insurer, the middleman and the drugstore at once.
Look, a breakup that lands conveniently while lawmakers are circling the PBM business is not a coincidence we're required to ignore. Maybe it's a genuine strategic reset. Maybe it's a company reading the room and shrinking the target before someone shrinks it for them. Either way, the structure that supposedly helped patients for nearly two decades is being quietly dismantled, and no one is apologizing for the $69 billion bet that built it.
The real tell is the name. The drugstore gets to be CVS Pharmacy, the clean one, the one with the friendly face. The insurer and the PBM keep the generic leftover title, the one nobody wants on a congressional witness list. That's not a business strategy. That's moving the valuables out of the house before the inspector arrives.
Comments